To efficiently deliver the chemotherapeutics to the tumor tissue and minimize the associated adverse effects, nucleolin targeted hybrid nanostructure based on hollow mesoporous silica nanoparticles (HMSNs) were fabricated. To provide the controlled, sustained drug release and enhance blood circulation, the surface of doxorubicin-encapsulated HMSNs were coated with acetylated carboxymethyl cellulose (Ac-CMC) and then covalently conjugated to AS1411 aptamer for guided drug delivery to nucleolin overexpressed cancerous cells. In vitro cellular uptake and cytotoxicity studies confirmed that AS1411 aptamer specifically targets nucleolin overexpressing MCF-7 and C26 cells. Moreover, the in vivo tumor inhibitory effect of AS1411 aptamer conjugated formulation demonstrated a superior therapeutic efficiency over non-targeted formulation and free doxorubicin.

The current study might open a new insight to the development of targeted intelligent hybrid materials based on AcCMC-coated HMSNs with high loading capacity, smart characteristics and desirable anticancer potential.

为了有效地将化学疗法递送至肿瘤组织并最小化相关的不良影响，制造了基于空心中孔二氧化硅纳米粒子（HMSN）的核仁素靶向的杂化纳米结构。为了提供可控的，持续的药物释放并增强血液循环，用乙酰化的羧甲基纤维素（Ac-CMC）包被阿霉素的HMSN表面包被，然后与AS1411适体共价缀合，以指导药物递送至过表达核仁素的癌细胞。体外细胞摄取和细胞毒性研究证实，AS1411适体特别靶向过表达核仁蛋白的MCF-7和C26细胞。而且，体内 AS1411适体偶联制剂的肿瘤抑制作用显示出优于非靶向制剂和游离阿霉素的优异治疗效果。

当前的研究可能会为基于高负载能力，智能特性和理想抗癌潜力的AcCMC涂层HMSN的靶向智能混合材料的开发开辟新的见解。